Incyte

Incyte (INCY) is a publicly traded company in the Health Care sector, specifically within the Biotechnology industry. Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

The company reports trailing twelve-month revenue of $3.39B and net income of $303.33M.

Key metrics include a return on equity of 5.4%, a debt-to-equity ratio of 0.31.

Investors tracking INCY can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.